| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHST9 |
| Uniprot No | Q7L1S5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-443aa |
| 氨基酸序列 | MQPSEMVMNPKQVFLSVLIFGVAGLLLFMYLQVWIEEQHTGRVEKRREQKVTSGWGPVKYLRPVPRIMSTEKIQEHITNQNPKFHMPEDVREKKENLLLNSERSTRLLTKTSHSQGGDQALSKSTGSPTEKLIEKRQGAKTVFNKFSNMNWPVDIHPLNKSLVKDNKWKKTEETQEKRRSFLQEFCKKYGGVSHHQSHLFHTVSRIYVEDKHKILYCEVPKAGCSNWKRILMVLNGLASSAYNISHNAVHYGKHLKKLDSFDLKGIYTRLNTYTKAVFVRDPMERLVSAFRDKFEHPNSYYHPVFGKAIIKKYRPNACEEALINGSGVKFKEFIHYLLDSHRPVGMDIHWEKVSKLCYPCLINYDFVGKFETLEEDANYFLQMIGAPKELKFPNFKDRHSSDERTNAQVVRQYLKDLTRTERQLIYDFYYLDYLMFNYTTPFL |
| 预测分子量 | 52 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CHST9重组蛋白的参考文献摘要概括：
1. **文献名称**：Carbohydrate Sulfotransferase 9 (CHST9) Facilitates Cell Adhesion by Regulating Sulfation of Glycosaminoglycans
**作者**：Smith et al. (2020)
**摘要**：研究利用HEK293细胞成功表达重组CHST9蛋白，证实其催化硫酸软骨素和硫酸皮肤素的磺化修饰，并发现该修饰增强细胞外基质黏附能力，提示CHST9在细胞迁移中的作用。
2. **文献名称**：Structural Characterization of Recombinant CHST9 and Its Role in Tumor Metastasis
**作者**：Zhang et al. (2018)
**摘要**：通过X射线晶体学解析重组CHST9蛋白三维结构，结合功能实验证明其异常表达促进肿瘤细胞表面糖链磺化，可能通过激活整合素信号通路驱动癌细胞转移。
3. **文献名称**：CHST9 Knockout Mice Reveal Defects in Hormone Glycosylation Patterns
**作者**：Tanaka et al. (2021)
**摘要**：利用重组CHST9蛋白制备特异性抗体，发现基因敲除小鼠垂体激素糖基化异常，导致生长激素生物活性下降，揭示了CHST9在内分泌调控中的新功能。
注：以上文献信息为模拟示例，实际文献需通过PubMed或Web of Science等学术平台检索确认。如需具体文献DOI或全文链接，建议补充关键词(如疾病模型或实验方法)进一步筛选。
**Background of CHST9 Recombinant Protein**
The CHST9 (Carbohydrate Sulfotransferase 9) protein belongs to the sulfotransferase family, which catalyzes the transfer of sulfate groups to carbohydrate moieties on glycoproteins, proteoglycans, or glycolipids. This post-translational modification, known as sulfation, plays a critical role in modulating molecular interactions, cellular signaling, and extracellular matrix organization. CHST9 specifically sulfates chondroitin and dermatan sulfate chains, influencing cell adhesion, inflammation, and pathogen recognition.
Recombinant CHST9 protein is engineered using biotechnological methods, typically expressed in mammalian or bacterial systems to ensure proper folding and enzymatic activity. Its production involves cloning the CHST9 gene into expression vectors, followed by purification via affinity chromatography. The recombinant form retains the native protein’s functional properties, enabling studies on sulfation mechanisms and substrate specificity.
Structurally, CHST9 contains conserved sulfotransferase domains, including a catalytic site binding the sulfate donor 3'-phosphoadenosine 5'-phosphosulfate (PAPS). Research highlights its involvement in diseases such as cancer, where altered glycosaminoglycan sulfation impacts tumor progression and metastasis. Additionally, CHST9 is studied in infectious diseases, as sulfated glycans can mediate host-pathogen interactions.
The availability of recombinant CHST9 facilitates drug discovery, biochemical assays, and structural studies, providing insights into its regulatory roles in health and disease. Its application extends to developing therapeutics targeting sulfation-dependent pathways, underscoring its biomedical significance.
×
